Key result
Chemotherapy is linked to a ~73% peak increase in LV free wall myocardial 18F-FDG uptake.
Why the study?
Cardiotoxicity from chemotherapy is often identified only after irreversible myocardial damage, and early metabolic changes detectable by 18F-FDG PET/CT may help in earlier detection.
Does chemotherapy induce early myocardial metabolic changes detectable by 18F-FDG PET/CT in lymphoma patients?
Population
62 lymphoma patients undergoing chemotherapy
Comparison
Myocardial 18F-FDG uptake before vs after chemotherapy
Design
Retrospective cohort study
Authors
Loading...
May support 18F-FDG PET/CT for early cardiotoxicity detection in lymphoma; leaves open prospective validation before clinical adoption.
Cohort (n=62)
No
Does chemotherapy induce early myocardial metabolic changes detectable by 18F-FDG PET/CT in lymphoma patients?
Mean Difference: 2.08 (95% CI 0.87–3.07)
Absolute Event Rate: 4.51% vs 2.43%
p-value: p=<0.001
18F-FDG PET/CT can detect early metabolic changes in the myocardium, particularly in the LV free wall, following chemotherapy in lymphoma patients, potentially serving as an early marker for cardiotoxicity.
Berenguer et al. (2025) conducted a cohort in Lymphoma (n=62). Chemotherapy vs. Baseline (pre-chemotherapy) was evaluated on Maximum 18F-FDG standardized uptake value (SUV) in the left ventricular free wall (MD 2.08, 95% CI 0.87-3.07, p=<0.001). Chemotherapy was associated with a significant global increase in myocardial 18F-FDG uptake, with the most pronounced elevation observed in the left ventricular free wall (maximum SUV increase of 73%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: